Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Jul 17, 2020Multizentrische Studie bei Patienten mit metastasiertem Nierenzellkarzinom nach Progredienz unter einer Erstli-nientherapie mit ICI/ICI oder ICI/TKI Kombination zur Eva-luation der Wirksamkeit und Verträglichkeit des Tyrosin-kinase Inhibitors Cabozan...
Clinical Studies - Jul 17, 2020 - Jul 17, 2022
Automatically Closed
Project leader: Rothermundt Christian
Members: Aeppli Stefanie, Fischer Stefanie, Omlin Aurelius
VeRVe: Observational study of the use of venetoclax in patients with chronic lymphocytic leukemia (CLL) under real-life setting in Austria,Germany and Switzerland (Venetoclax Real Value)
Jul 15, 2020
Clinical Studies - Jul 15, 2020 - Sep 27, 2022
Automatically Closed
Project leader: Baumann Michael
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembroli-zumab for First-Line Treatment of PD-L1 Positive Recur-rent/Metastatic Head and Neck Squamous Cell Carcinoma
Jul 10, 2020The study will evaluate the efficacy of GSK3359609 in combination with pembrolizumab compared with pem-brolizumab plus placebo as a standard first-line chemo-therapy-free regimen in HNSCC. All participants will be stratified by 2 factors i) PD-L1 CPS...
Clinical Studies - Jul 10, 2020 - Jul 31, 2021
Automatically Closed
Project leader: Jörger Markus
Protocol SAKK 11/16: Personalized and cell-based anti-tumor immunization MVX-ONCO-1 in advanced head and neck squamous cell carcinoma. A single arm, open label, multicenter phase II trial
Jul 10, 2020MVX-ONCO-1 is a form of active specific immunotherapy, a process by which the patient’s immune response to tumor cells is stimulated and/or augmented. MVX-ONCO-1 is a patient specific, cell-based, immunotherapy composed of: a. An immune-modulator (...
Clinical Studies - Jul 10, 2020 - Nov 8, 2023
Completed
Project leader: Rordorf Tamara
Characterization of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland
Jul 7, 2020Mit der vorliegenden Studie sollen Daten von Patienten, die eine Therapie im ZIM in Anspruch genommen haben, nach demografischen und krankheits-spezifischen Charakteristika ausgewertet werden. Dies ermöglicht die Anpassung des bestehenden Angebotes a...
Clinical Studies - Jul 7, 2020 - Jul 7, 2021
Completed
Project leader: Schlaeppi Marc, Templeton Arnoud
Members: Schlegel Tiffany
The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo
Jul 1, 2020We here aim to dissect the molecular landscape of MM that is acquiring resistance to the most active PI, carfilzomib (CFZ) in vivo. We therefore here extend our model to orthotopic growth conditions of MM in murine bone marrow under continuous select...
Fundamental Research - Jul 1, 2020 - Dec 31, 2023
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Schwestermann Jonas, Kraus Marianne, Besse Lenka
Lymphopenie bei myeloproliferativen Neoplasien: Prävalenz und prognostische Bedeutung
Jul 1, 2020Eine Lymphopenie als Ausdruck einer Störung des adaptiven Immunsystems ist ein etablierter Risikofaktor bei verschiedenen Allgemein- und Tumorerkrankungen. Im Hinblick auf myeloische Neoplasien konnte im Rahmen eines Kooperationsprojektes des KSSG m...
Clinical Studies - Jul 1, 2020 - Jun 30, 2022
Automatically Closed
Project leader: Silzle Tobias
Members: Messerich Nora-Medea, Cogliatti Sergio B., Lehmann Thomas, Graf Lukas
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD - L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III ( N2) non -small cell lung cacner (NSCLC)
Apr 29, 2020Evaluation einer immunmodulatorischen neoadjuvanten Radiotherapie in verschiedenen Dosen nach neoadjuvanter Chemotherapie mit Cisplatin und Docetaxel bei Patienten mit operablem, lokal fortgeschrittenem (Stadium IIIA) Nicht-Kleinzelligen Bronchialkar...
Clinical Studies - Apr 29, 2020 - Aug 24, 2030
Ongoing
Project leader: Früh Martin
Members: Sakic Miranda, Müller Fiona
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolera-bility, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients with Locally Ad-vanced or Metastatic Solid Tumour Malignancies Charac-terised by Alterations of the NOTCH Signalling Pathway
Apr 17, 2020This study is designed as an open label, non-randomised, uncontrolled Phase I/IIA dose escalation study with expan-sion cohorts of CB-103 administered orally on a once-daily schedule, based on a 28-day treatment cycle. The admin-istration schedule ma...
Clinical Studies - Apr 17, 2020 - May 26, 2030
Ongoing
Project leader: Hess Dagmar
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic HormoneSensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Mar 3, 2020While many men diagnosed with locally confined disease may be treated definitively with radiation or surgery, ap-proximately 30% of men have recurrent disease and go on to develop metastatic prostate cancer. In addition, 5% to 30% of men with prostat...
Clinical Studies - Mar 3, 2020 - Mar 10, 2030
Ongoing
Project leader: Omlin Aurelius
Members: Rothermundt Christian, Aeppli Stefanie
Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreat-ed, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Mar 3, 2020CA20973L is a phase 3, randomized, open label study to compare nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab or nivolumab alone versus CCRT followed by durvalumab in previously untreated locally advanced non...
Clinical Studies - Mar 3, 2020 - Mar 10, 2029
Ongoing
Project leader: Früh Martin
Revealing molecular basis of cardiotoxicity of carfilzomib towards its safer use in the patients with multiple myeloma
Mar 1, 2020
Fundamental Research - Mar 1, 2020 - Feb 28, 2021
Automatically Closed
Project leader: Besse Lenka
Members: Mendez Lopez Max
KSSG Collaborative Brain Tumour Registry
Jan 16, 2020Primary brain tumours remain an important burden of disease in Switzerland. Between 2010 – 2014, there were 1570 incident cases and about 580 deaths attributed to brain tumours each year. Although tumours of the central nervous system (CNS) represent...
Clinical Studies - Jan 16, 2020 - Jan 16, 2025
Ongoing
Project leader: Zeitlberger Anna, Hundsberger Thomas
Predictive markers for checkpoint-based immunotherapy in advanced non-small cell lung cancer
Jan 1, 2020The aim of this study is to elucidate a novel biomarker constellation with superior predictive value for PD-1/PD-L1-targeted immunotherapy in advanced non-small cell lung cancer.
Fundamental Research - Jan 1, 2020 - Dec 31, 2021
Completed
Project leader: Bösch Maximilian
Members: Baty Florent, Brutsche Martin, Früh Martin, Jörger Markus
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019Klinisches Register des „Europäischen Mantelzelllymphom Netzwerk (EMCL)“. Erfassung von Patienten mit neu diag-nostiziertem oder rezidiviertem Mantelzelllymphom
Clinical Studies - Dec 20, 2019 - Dec 20, 2025
Ongoing
Project leader: Fehr Martin
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019
Clinical Studies - Dec 20, 2019 - Dec 31, 2030
Ongoing
Project leader: Fehr Martin
Members: Steiner Marianne
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Dec 18, 2019IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...
Clinical Studies - Dec 18, 2019 - Jan 31, 2027
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
A Phase 1b/2 Multicenter, Open-label, Expansion Study to As-sess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Dec 5, 2019Bispezifische, T-Zell-aktivierende Antikörper (BITE) sind eine vielversprechende Option, um eine zellvermittelte Immuntherapie von Tumoren zu erreichen. In der vorlie-genden Studie wird die Wirksamkeit und Sicherheit eines gegen das Oberflächenantige...
Clinical Studies - Dec 5, 2019 - Dec 23, 2020
Automatically Closed
Project leader: Driessen Christoph
Members: Silzle Tobias
SAKK 66/18: A phase Ib trial of copanlisib in combina-tion with venetoclax in patients with relapsed or refrac-tory lymphoma
Sep 13, 2019A significant number of patients with non-Hodgkin lym-phoma (NHL) are not cured with available treatments and will eventually relapse. Those patients might not be able to tolerate more bone marrow toxicity, limiting their treatment options. Preclinic...
Clinical Studies - Sep 13, 2019 - Dec 31, 2022
Automatically Closed
Project leader: Hess Dagmar
A phase I/Ib, open-label, multi-center dose escalation study of NIS793 in combination with PDR001 in adult patients with advanced malignancies (CNIS793X2101)
Sep 9, 2019This is a first-in-human (FIH), open label, phase I/Ib, multi-center study which consists of: - a dose escalation part of NIS793 as single agent and in combination with PDR001. Patients treated with NIS793 single agent will switch to NIS793 in combin...
Clinical Studies - Sep 9, 2019 - Jul 1, 2021
Automatically Closed
Project leader: Jörger Markus